10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2012 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 27, 2013) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Revenues [Abstract] | |||
| Product Sales | $ 9,398,371 | 8,102,359 | 7,389,921 |
| Royalty Revenues | 290,523 | 268,827 | 545,970 |
| Contract and Other Revenues | 13,623 | 14,199 | 13,529 |
| Total Revenues | 9,702,517 | 8,385,385 | 7,949,420 |
| Costs and Expenses [Abstract] | |||
| Cost of Goods Sold | 2,471,363 | 2,124,410 | 1,869,876 |
| Research and Development Expenses | 1,759,945 | 1,229,151 | 1,072,930 |
| Selling, General and Administrative Expenses | 1,461,034 | 1,241,983 | 1,044,392 |
| Total Costs and Expenses | 5,692,342 | 4,595,544 | 3,987,198 |
| Income from Operations | 4,010,175 | 3,789,841 | 3,962,222 |
| Interest Expense | (360,916) | (205,418) | (108,961) |
| Other Income (Expense), net | (37,279) | 66,581 | 60,287 |
| Income Before Provision for Income Taxes | 3,611,980 | 3,651,004 | 3,913,548 |
| Provision for Income Taxes | 1,038,381 | 861,945 | 1,023,799 |
| Net Income | 2,573,599 | 2,789,059 | 2,889,749 |
| Net Loss Attributable to Noncontrolling Interest | 17,967 | 14,578 | 11,508 |
| Net Income Attributable to Gilead | 2,591,566 | 2,803,637 | 2,901,257 |
| Net Income Per Share Attributable to Gilead Common Stockholders - Basic (usd per share) | 1.71 | 1.81 | 1.69 |
| Shares Used in Per Share Calculation-Basic (shares) | 1,514,621 | 1,549,806 | 1,712,120 |
| Net Income Per Share Attributable to Gilead Common Stockholders - Diluted (usd per share) | 1.64 | 1.77 | 1.66 |
| Shares Used in Per Share Calculation - Diluted (shares) | 1,582,549 | 1,580,236 | 1,746,792 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2012 | |||
Consolidated Statements of Comprehensive Income | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 27, 2013) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Net Income | $ 2,573,599 | 2,789,059 | 2,889,749 |
| Net Foreign Currency Translation Gain (Loss) | 11,076 | (5,264) | (8,416) |
| Net Unrealized Gain (Loss), Net of Tax Impact of $(703), $(3,305) and $(6,624) for the Year Ended December 31, 2012, 2011 and 2010, Respectively | 1,242 | (24,067) | 13,450 |
| Reclassifications to Net Income, Net of Tax Impact of $849, $(11,114) and $(3,167) for the Year Ended December 31, 2012, 2011 and 2010, Respectively | 33,008 | (19,209) | (6,430) |
| Net Change | 34,250 | (43,276) | 7,020 |
| Net Unrealized Gain (Loss), Net of Tax Impact of $1,566, $(93) and $(9,149) for the Year Ended December 31, 2012, 2011 and 2010, Respectively | (62,505) | 1,571 | 105,924 |
| Reclassifications to Net Income, Net of Tax Impact of $(2,171), $4,389 and $(5,861) for the Year Ended December 31, 2012, 2011 and 2010, Respectively | (86,636) | 74,258 | (67,859) |
| Net Change | (149,141) | 75,829 | 38,065 |
| Other Comprehensive Income (Loss) | (103,815) | 27,289 | 36,669 |
| Comprehensive Income | 2,469,784 | 2,816,348 | 2,926,418 |
| Comprehensive Loss Attributable to Noncontrolling Interest | 17,967 | 14,578 | 11,508 |
| Comprehensive Income Attributable to Gilead | 2,487,751 | 2,830,926 | 2,937,926 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2012 | |||
Statement of Cash Flows | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 27, 2013) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Net Cash Provided by (Used in) Operating Activities [Abstract] | |||
| Net Income | $ 2,573,599 | 2,789,059 | 2,889,749 |
| Adjustments to Reconcile Net Income to Cash Provided by Operating Activities [Abstract] | |||
| Depreciation Expense | 82,847 | 72,187 | 67,240 |
| Amortization Expense | 195,359 | 230,045 | 198,237 |
| Stock-Based Compensation Expense | 208,725 | 192,378 | 200,041 |
| In-Process Research and Development Impairment Expense | 0 | 26,630 | 136,000 |
| Excess Tax Benefits from Stock-Based Compensation | (114,236) | (40,848) | (81,620) |
| Tax Benefits from Employee Stock Plans | 112,629 | 37,231 | 82,086 |
| Deferred Income Taxes | (39,393) | 64,061 | 12,152 |
| Other | (1,878) | 47,931 | 10,408 |
| Increase (Decrease) in Operating Capital [Abstract] | |||
| Accounts Receivable, net | 197,986 | (375,736) | (348,875) |
| Inventories | (349,924) | (200,793) | (161,190) |
| Prepaid Expense and Other Assets | (129,318) | (13,959) | (70,466) |
| Accounts Payable | 117,485 | 428,944 | (4,453) |
| Income Taxes Payable | (68,473) | 110,771 | (185,733) |
| Accrued Liabilities | 386,063 | 300,593 | 120,065 |
| Deferred Revenue | 23,245 | (29,484) | (29,728) |
| Net Cash Provided by Operating Activities | 3,194,716 | 3,639,010 | 2,833,913 |
| Net Cash Provided by (Used in) Investing Activities [Abstract] | |||
| Purchases of Marketable Securities | (1,244,898) | (5,127,790) | (5,502,687) |
| Proceeds from Sales of Marketable Securities | 527,712 | 8,649,752 | 3,033,893 |
| Proceeds from Maturities of Marketable Securities | 44,813 | 788,395 | 683,927 |
| Purchases of Other Investments | (25,000) | 0 | 0 |
| Acquisitions, Net of Cash Acquired | (10,751,635) | (588,608) | (91,000) |
| Capital Expenditures | (397,046) | (131,904) | (61,884) |
| Net Cash Provided by (Used in) Investing Activities | (11,846,054) | 3,589,845 | (1,937,751) |
| Net Cash Provided by (Used in) Financing Activities [Abstract] | |||
| Proceeds from debt financing, net of issuance costs | 2,144,733 | 4,660,702 | 2,962,500 |
| Proceeds from convertible note hedges | 213,856 | 36,148 | 0 |
| Proceeds from Sale of Warrants | 0 | 0 | 155,425 |
| Proceeds from Issuances of Common Stock | 466,283 | 211,737 | 221,223 |
| Purchases of convertible note hedges | 0 | 0 | (362,622) |
| Repurchases of Common Stock | (667,041) | (2,383,132) | (4,022,593) |
| Repayments of Debt Financing | (1,837,139) | (686,135) | (500,000) |
| Repayments of Other Long-Term Obligations | (2,186) | (1,562) | (5,786) |
| Excess Tax Benefits from Stock-Based Compensation | 114,236 | 40,848 | 81,620 |
| Contributions From (Distributions to) Noncontrolling Interest | 130,604 | (115,037) | 131,523 |
| Net Cash Provided by (Used in) Financing Activities | 563,346 | 1,763,569 | (1,338,710) |
| Effect of Exchange Rate Changes on Cash | 7,909 | (16,526) | 77,469 |
| Net Change in Cash and Cash Equivalents | (8,080,083) | 8,975,898 | (365,079) |
| Cash and Cash Equivalents at beginning of period | 9,883,777 | 907,879 | |
| Cash and Cash Equivalents at end of period | 1,803,694 | 9,883,777 | 907,879 |
| Supplemental Cash Flow Information [Abstract] | |||
| Interest paid, net of amounts capitalized | 249,358 | 62,180 | 15,748 |
| Income Taxes Paid | 1,101,241 | 621,025 | 1,129,577 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
GILEAD SCIENCES, INC. | ||
Ticker: GILD Fiscal Year: 2012 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2012 10-K (Filed: Feb 27, 2013) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2012 | Dec 31, 2011 | |
| Assets [Abstract] | ||
| Cash and Cash Equivalents | $ 1,803,694 | 9,883,777 |
| Short-Term Marketable Securities | 58,556 | 16,491 |
| Accounts Receivable, Net of Allowances of $261,013 at December 31, 2012 and $205,990 at December 31, 2011 | 1,751,388 | 1,951,167 |
| Inventories | 1,744,982 | 1,389,983 |
| Deferred Tax Assets | 262,641 | 208,155 |
| Prepaid Taxes | 348,420 | 246,444 |
| Prepaid Expenses and Other Current Assets | 186,666 | 222,768 |
| Total Current Assets | 6,156,347 | 13,918,785 |
| Property, Plant and Equipment, Net | 1,100,259 | 774,406 |
| Long-Term Portion of Prepaid Royalties | 175,790 | 174,584 |
| Long-Term Deferred Tax Assets | 131,107 | 144,015 |
| Long-term Marketable Securities | 719,836 | 63,704 |
| Intangible Assets, Net | 11,736,393 | 1,062,864 |
| Goodwill | 1,060,919 | 1,004,102 |
| Other Long-Term Assets | 159,187 | 160,674 |
| Total Assets | 21,239,838 | 17,303,134 |
| Liabilities and Stockholders' Equity [Abstract] | ||
| Accounts Payable | 1,327,339 | 1,206,052 |
| Accrued government rebates | 745,148 | 547,473 |
| Accrued Compensation and Employee Benefits | 236,716 | 173,316 |
| Income Taxes Payable | 13,403 | 40,583 |
| Other Accrued Liabilities | 674,762 | 471,129 |
| Deferred Revenues | 103,162 | 74,665 |
| Current Portion of Long-Term Debt and Other Obligations, net | 1,169,490 | 1,572 |
| Total Current Liabilities | 4,270,020 | 2,514,790 |
| Long-Term Deferred Revenues | 20,532 | 31,870 |
| Long-Term Debt, net | 7,054,555 | 7,605,734 |
| Long-Term Income Taxes Payable | 115,822 | 135,655 |
| Other Long-Term Obligations | 228,040 | 147,736 |
| Stockholders' Equity [Abstract] | ||
| Preferred Stock, Par Value $0.001 Per Share; 5,000 Shares Authorized; None Outstanding | 0 | 0 |
| Common Stock, Par Value $0.001 Per Share; 2,800,000 Shares Authorized; 1,519,163 and 1,506,212 Shares Issued and Outstanding at December 31, 2012 and December 31, 2011, Respectively | 760 | 753 |
| Additional Paid-in Capital | 5,649,850 | 4,903,143 |
| Accumulated Other Comprehensive Income (Loss) | (45,615) | 58,200 |
| Retained Earnings | 3,704,744 | 1,776,760 |
| Total Gilead Stockholders' Equity | 9,309,739 | 6,738,856 |
| Noncontrolling Interest | 241,130 | 128,493 |
| Total Stockholders' Equity | 9,550,869 | 6,867,349 |
| Total Liabilities and Stockholders' Equity | 21,239,838 | 17,303,134 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |